PMID- 20065428
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151026
LR  - 20100112
IS  - 0023-7213 (Print)
IS  - 0023-7213 (Linking)
VI  - 82
IP  - 11
DP  - 1996 Nov
TI  - [New developments in anticoagulation with heparin; a short review.].
PG  - 778-83
AB  - Low molecular-weight heparins (LMWH) are derivatives of standard unfractionated 
      heparin (UFH) and both types of heparins are used for anticoagulation. UFH is 
      heterogeneous with respect to molecular size and exerts its effect through 
      enhancement of antithrombin III inhibition of serine proteases. Full dose UFH has 
      a narrow therapeutic window as well as a short half-life and this mandates 
      constant monitoring of its anticoagulatory effect. Weight-based dosing guidelines 
      for unfractionated heparin have been shown to be safe and improve results. New 
      modified heparins have lower molecular weight (LMWH) than UFH. The LMWH are dosed 
      according to body weight without a need for monitoring tests and subcutaneous 
      administration no more than twice daily is adequate. In studies comparing LMWH to 
      UFH, the LMWH seem to be at least as effective as unfractionated heparin in 
      preventing or treating venous thromboembolism. To date the comparison in these 
      studies has been between LMWH and UFH dosed in the traditional way but a 
      comparison of LMWH with UFH dosed by weight-based guidelines has not been studied 
      yet.
FAU - Gudmundsson, S
AU  - Gudmundsson S
FAU - Onundarson, P T
AU  - Onundarson PT
LA  - ice
PT  - English Abstract
PT  - Journal Article
PL  - Iceland
TA  - Laeknabladid
JT  - Laeknabladid
JID - 7901326
EDAT- 1996/11/01 00:00
MHDA- 1996/11/01 00:01
CRDT- 2010/01/13 06:00
PHST- 2010/01/13 06:00 [entrez]
PHST- 1996/11/01 00:00 [pubmed]
PHST- 1996/11/01 00:01 [medline]
PST - ppublish
SO  - Laeknabladid. 1996 Nov;82(11):778-83.